Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PEPD | P12955 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 3/20 | 0.33 |
| ▸ | REN | P00797 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19947221 | 0.84 | L3MBTL1 (0.38) | L3MBTL1ATMRAB9APOLBACE | |
| SCHEMBL19947204 | 0.84 | L3MBTL1 (0.38) | L3MBTL1ATMRAB9APOLBPEPD | |
| SCHEMBL19965312 | 0.82 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL19963364 | 0.82 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL18281690 | 0.77 | ATM (0.46) | L3MBTL1ATM | |
| SCHEMBL14668787 | 0.76 | POLB (0.41) | L3MBTL1RAB9APOLBPEPDACE | |
| SCHEMBL29481523 | 0.74 | POLB (0.42) | L3MBTL1RAB9APOLBPEPDACE | |
| SCHEMBL28153696 | 0.74 | POLB (0.42) | L3MBTL1RAB9APOLBFFAR1 | |
| SCHEMBL5643023 | 0.74 | POLB (0.42) | L3MBTL1RAB9APOLBFFAR1 | |
| SCHEMBL18281730 | 0.74 | FFAR1 (0.46) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246462-B2 | Chemokine receptor modulators and uses thereof | FLX BIO, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| WO-2018049271-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246462-B2 | Chemokine receptor modulators and uses thereof | ACKR3, CCR5, CXCR3 | L3MBTL1 3976/4885ATM 4327/4885RAB9A 2121/4885 |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | L3MBTL1 3976/4885ATM 4327/4885RAB9A 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.